🔴 Cue Biopharma is trading 6.1% down today after second-quarter net loss widened to $153.1 million

Cue Biopharma is trading 6.1% down at $32.12 after investors reassessed its August 14 second-quarter results.

• Revenue rose to $7.9 million from $3.0 million; net loss widened to $153.1 million, including substantial one-time licensing and non-cash warrant charges.
• $50 million private placement and upcoming CUE-221 Phase 2 data left financing and execution concerns in focus.
• August 14’s 10.04% gain preceded the decline, suggesting profit-taking and renewed loss scrutiny; no separate August 17 announcement clearly explains it.